title: The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.
abstract: This article examines the current use and future implications of stem cell therapy in treating Multiple Sclerosis (MS). MS is the most common neurological disease in young adults, affecting approximately two million people worldwide. Currently there is no cure for MS. The standard treatment of MS involves disease-modifying drugs, which work to alleviate the symptoms of MS. However, these drugs carry adverse side effects and are ineffective in preventing disease progression in many MS patients. Hematopoietic stem cell transplantation (HSCT) was first used in 1995 to treat patients with severe rapidly progressing MS. The HSCT treatment protocol has evolved into a less intense conditioning regimen that is currently demonstrating efficacy in treating patients with variable disease severity-with best results in early-stage rapidly progressing MS patients with active CNS inflammation. Mesenchymal stem cell therapy (MSCT) is an experimental stem cell therapy currently undergoing clinical trials. Animal models and early clinical trials have shown promise that MSCT might be a low risk treatment to precipitate neuroregeneration and immunomodulation in MS patients. Specifically, neuroprogenitor and placental-derived mesenchymal stem cells offer the best hope for a practical treatment for MS. Stem cell therapy, and perhaps a combinatorial therapeutic approach, holds promise for a better treatment for MS.
authors.affiliation: Department of Biochemistry and Molecular & Cellular Biology, Georgetown University School of Medicine 3900 Reservoir Rd. NW, Washington DC 20057, USA.
authors.forename: Jameson P
authors.initials: JP
authors.lastname: Holloman
authors.forename: Calvin C
authors.initials: CC
authors.lastname: Ho
authors.forename: Arushi
authors.initials: A
authors.lastname: Hukki
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Huntley
authors.forename: G Ian
authors.initials: GI
authors.lastname: Gallicano
keywords: Multiple sclerosis; autologous hematopoietic stem transplantation; mesenchymal stem cell transplantation; stem cells